Recent Company News

• 07:38 PM ET Sep 16, 2025
  

  Eisai receives FDA Fast Track Designation for Etalanetug (¥5183.0000, 0)

• 12:08 AM ET Sep 08, 2025
  

  Eisai's E2086 shows statistically significant effectiveness in individuals with NT1 from Phase Ib clinical trial (¥5315.0000, +178)

• 07:34 PM ET Sep 02, 2025
  

  Eisai initiates rolling submission of sBLA to the FDA for lecanemab-irmb SC-AI ($139.63, 0.00)

• 05:13 PM ET Aug 29, 2025
  

  FDA Approves LEQEMBI IQLIK (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer's Disease ($132.22, 0.00)

• 03:02 AM ET Aug 29, 2025
  

  Eisai receives orphan drug designation in Japan for Tazemetostat for unresectable INI1-Negative Epithelioid Sarcoma (¥4538.0000, 0)

• 11:57 AM ET Aug 28, 2025
  

  FDA recommends additional MRI monitoring for patients taking Leqembi ($134.00, -2.36)

• 03:04 AM ET Aug 25, 2025
  

  Biogen, Eisai to launch LEQEMBI in Austria today ($139.31, 0.00)

• 07:47 PM ET Aug 17, 2025
  

  Eisai launches in-house developed anti-insomnia drug DAYVIGO (lemborexant) in China (¥4638.0000, 0)

• 01:10 AM ET Aug 12, 2025
  

  Newron Pharmaceuticals begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS) (CHF 7.74, 0.00)

• 01:03 AM ET Aug 11, 2025
  

  Newron Pharmaceuticals notes the publication of new preclinical research suggesting evenamide ameliorates schizophrenia-related dysfunction (CHF 7.47, 0.00)